Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2008, vol. 17, nr 2, March-April, p. 123–128

Publication type: editorial article

Language: English

Prorenin/Renin and Their Receptors – a Potential Role in Diabetic Kidney Disease

Prorenina/renina i ich receptory – potencjalna rola w cukrzycowej chorobie nerek

Stanisław Czekalski1,

1 Department of Nephrology, Transplantology, and Internal Diseases, Poznan University of Medical Sciences, Poznań, Poland

Abstract

The discovery of specific renin/prorenin receptors, termed (pro)renin receptors, initiated several studies on the pathological role of prorenin. The association of high prorenin levels with the development of kidney injury in diabetes suggested that prorenin itself may induce diabetic nephropathy. Prorenin can be activated in two ways: a proteolytic and a nonproteolytic. When bound to a (pro)renin receptor, prorenin displays full enzymatic activity through the nonproteolytic way, but it not only facilitates angiotensin generation, but also causes activation of intracellular signaling independent of angiotensin. This review presents current data which characterize the role of the renin/prorenin−(pro)renin receptor system particularly in diabetic nephropathy and the results of studies on the inhibition of this system in experimental diabetic animals.

Streszczenie

Odkrycie receptorów reniny/proreniny, określanych jako receptory (pro)reniny, zapoczątkowało liczne badania nad oceną znaczenia proreniny w patologii. Związek dużych stężeń proreniny w osoczu z rozwojem uszkodzenia nerek u chorych na cukrzycę sugerował, że sama prorenina może wpływać na rozwój nefropatii cukrzycowej. Prorenina może być aktywowana dwiema drogami: proteolityczną i nieproteolityczną. Po związaniu z receptorem (pro)reniny uzyskuje pełną aktywność enzymatyczną na drodze nieproteolitycznej, ale nie tylko zwiększa powstawanie angiotensyny, lecz również powoduje aktywację przekaźnictwa wewnątrzkomórkowego niezależnego od angiotensyny. W niniejszej pracy poglądowej przedstawiono aktualne dane charakteryzujące rolę układu renina/prorenina–receptor (pro)reniny w nefropatii cukrzycowej oraz wyniki badań nad hamowaniem tego układu w doświadczalnej cukrzycy u zwierząt.

Key words

renin/prorenin, (pro)renin receptor, diabetic nephropathy, inhibition of (pro)renin receptor

Słowa kluczowe

renina/prorenina, receptor (pro)reniny, nefropatia cukrzycowa, hamowanie receptora (pro)reniny

References (31)

  1. Nguyen G: Renin/prorenin receptors. Kidney Int 2006, 69, 1503–1506.
  2. De Lannoy LM, Danser AH, van Kats JP, Schoemaker RC, Saxena PR, Schalekamp MA: Renin−angiotensin system compartments in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997, 29, 1240–1251.
  3. Muller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Menerd J, Busjahn A, Genten D, Luft FC: Local angiotensis II generation in the heart: role of renin uptake. Clin Res 1998, 82, 13–20.
  4. Allen TJ, Cooper ME, Gilbert RE, Winikoff J, Skiuni SL, Jerums G: Serum total renin is increased before microalbuminuria in diabetes. Kidney Int 1996, 50, 902–907.
  5. Sealey JE, White RP, Laragh JH, Rubin AI: Plasma prorenin and renin in anephric patients. Circ Res 1977, 41, 17–21.
  6. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W: Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circ Rec 1997, 80, 219–227.
  7. Admiraal PJJ, van Kesteren CAM, Danser AHJ, Derkx FH, SluiterW, Schalekamp MA: Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens 1999, 17, 621–629.
  8. Saris JJ, Derkx FHM, de Briun RJA, Dekkers DH, Lamers MJ, Saxena PR Schalekamp MA, Jan DanserAH: High−affinity prorenin binding to cardiac man−6−P/IGF II receptor precedes proteolytic activation to renin. Am J Physiol 2001, 280, H1706–H1715.
  9. Peters J, Farrenkopf R, Clausmeyer S Zimmer J, Kantachuvesiri S, Skorp MG, Mullins JJ: Functional significance of prorenin internalization in the rat heart. Circ Res 2002, 90, 1135–1141.
  10. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor−1 antigen. Kidney Int 1996, 50, 1897–1903.
  11. Nguyen G, Delarue F, Burckle C, Bonzhir L, Giller T, Sraer J−D: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109, 1417–1427.
  12. Nguyen G: The pro(renin) receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens 2007, 16, 129–133.
  13. Burckle C, Bader M: Prorenin and its ancien receptor. Hypertension 2006, 48, 549–551.
  14. Nguyen G, Bouzkir L, Delarue F, Rondeau E, Sraer JD: Evidence for a renin receptor on human mesangial cells: effects on PAI1 and cGMP. Nephrologie 1998, 19, 411–416.
  15. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, Nakamura Y, Murakami K: Human prorenin has “gate” and “handle” regions for its non−proteolytic activation. J Biol Chem 2003, 278, 22217–22222.
  16. Takahashi H, Ichihava A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H: Regression of nephropathy developed in diabetes by (Pro)rennin receptor blockade. J Am Soc Nephrol 2007, 18, 2054–2061.
  17. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Liddin NM, Nabi AHNM, Ishida Y, Inagami T, Saruta T: Inhibition of diabetic nephropathy by decoy peptide corresponding to the ‘handle’ region for nonproteolytic activation of prorenin. J Clin Invest 2004, 114, 1128–1135.
  18. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006, 47, 894–900.
  19. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W: Renin increases mesangial cell transforming growth factor−beta1 and matrix proteins through receptor mediated, angiotensin II−independent mechanisms. Kidney Int 2006, 69, 105–113.
  20. Saris JJ, ‘t Hoen PAC, Gerrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH: Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006, 48, 1–8.
  21. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer−Ash M: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985, 312, 1412–1417.
  22. Daneman D, Crompton CH, Balfe JW, Sochett EB, Chatzilias A, Cotter BR, Osmond DH: Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int 1994, 46, 1154–1159.
  23. Olivier JA: Receptor−mediated actions of renin and prorenin. Kidney Int 2006, 69, 13–15.
  24. Song RH, Singh AK, Leekey DJ: Decreased glomerular proteinase activity in the streptozotocin diabetic rat. Am J Nephrol 1999, 19, 441–446.
  25. Veniant M, Menard J, Bruneval P, Morley S, Gouzales MF, Mullins J: Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996, 98, 1966–1970.
  26. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the rennin system. Hypertension 1998, 32, 387–392.
  27. Huang Y, Noble N, Zhang J, Xu C, Border WA: Renin stimulated TGF−β1 expression is regulated by a mitogen−activated protein kinase in mesangial cells. Kidney Int 2007, 72, 45–52.
  28. Ischihara A, Suzuki F, Natagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AHMN, Nishiyama A, Sugaya T, Hayaski M, Inagami T: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor deficient mice. J Am Soc Nephrol 2006, 17, 1950–1961.
  29. Nguyen G: The (pro)renin receptor: A new kid in town. Seminars in Nephrology 2007, 27, 519–523.
  30. Peters B, Grisk O, Becher B, Wanka H, Kutfler B, Lüdeman J, Lorenz G, Rettig R, Mullins JJ, Peters J: Dose−dependent titration of prorenin and blood pressure in Cyp1a1ren−2 transgenic rats: absence of prorenininduced glomerulosclerosis. J Hypertens 2008. 26, 102–109.
  31. Brosnan MJ: Prorenin and glomerulosclerosis? J Hypertens 2008, 26, 14–15.
© Wroclaw Medical University